RJA
ORIC icon

Raymond James & Associates’s Oric Pharmaceuticals ORIC Stock Holding History

Raymond James & Associates’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,816
Closed -$412K – 4165
2021
Q1 		$412K Sell
16,816
-10,025
-37% -$317K ﹤0.01% 3151
2020
Q4 		$909K Sell
26,841
-9,385
-26% -$269K ﹤0.01% 2413
2020
Q3 		$906K Buy
36,226
+5,941
+20% +$141K ﹤0.01% 2230
2020
Q2 		$1.02M Buy
+30,285
New +$967K ﹤0.01% 2148

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Raymond James & Associates's ORIC Position: Q2 2021 in Review

Raymond James & Associates sold out of Oric Pharmaceuticals (ORIC) in Q2 2021, closing a stake of 16,816 shares — an estimated $412K sold.

Raymond James & Associates first reported a position in ORIC in Q2 2020 and held it in 4 quarters. The position peaked at $1.02M in Q2 2020. 78 funds tracked by Wall St. Rank hold ORIC as of Q2 2021.

  • Raymond James & Associates reported no remaining Oric Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 16,816 Oric Pharmaceuticals shares in Q2 2021, an estimated $412K.
  • Raymond James & Associates first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • Raymond James & Associates's Oric Pharmaceuticals position peaked at $1.02M in Q2 2020.
  • 78 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.